Viking Therapeutics, Inc. (VKTX)
| Market Cap | 7.07B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -85.90M |
| Shares Out | 109.36M |
| EPS (ttm) | -0.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,380,846 |
| Open | 66.13 |
| Previous Close | 66.47 |
| Day's Range | 64.50 - 66.25 |
| 52-Week Range | 8.28 - 99.41 |
| Beta | 1.10 |
| Analysts | Strong Buy |
| Price Target | 95.40 (+47.52%) |
| Earnings Date | Apr 24, 2024 |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phas... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price forecast is $95.4, which is an increase of 47.52% from the latest price.
News
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Conference Call Scheduled for Wednesday, April 24 at 4:30 p.m. Eastern Time SAN DIEGO , April 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmace...
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Viking Files Registration Statement with SEC for Proposed Initial Public Offering
LOS ANGELES, April 5, 2024 /PRNewswire/ -- Viking Holdings Ltd ("Viking") today announced that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commissi...
Healthcare stocks fade as obesity-drug optimism fades
Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.
Viking Therapeutics' positive results for oral weight-loss drug has analysts backing buy ratings
Viking Therapeutics Inc.'s stock rose 1.9% early Wednesday to add to its prior-day gains, as analysts welcomed positive data from the company's early trial of an oral weight-loss treatment — the lates...
Topping the tape: Viking soars on oral weight loss drug
The 'Fast Money' traders weigh in on Viking Thera stock soaring on its obesity pill data.
Viking Therapeutics stock ($VKTX) pops 20% on oral weight-loss drug trial data
Viking Therapeutics Inc (NASDAQ: VKTX) is up nearly 20% on Tuesday after reporting encouraging early-stage data for its experimental weight-loss oral drug. Is Viking Therapeutics' oral weight-loss dru...
Viking Therapeutics stock jumps 15% on promising weight loss pill data
The Viking study results add to the growing excitement around the biotech company and its potential in the budding weight loss market.
Viking Therapeutics says its experimental tablet reduced weight in early-stage study
Viking Therapeutics said on Tuesday its experimental tablet helped reduce weight in patients in an early-stage trial and was shown to be safe and effective in the study.
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events Phase 2 ...
Wegovy and Zepbound Are King. Who's Coming for Their Crowns.
Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.
Viking Therapeutics faces higher bar for oral weight-loss drug after strong readout from rival
Viking Therapeutics Inc.'s stock fell 5.6% Friday, in a pullback from recent highs, after strong data from Novo Nordisk on an oral version of its weight-loss drug raised the competitive bar for Viking...
The Emergence of Strong Weight Loss Drug Players
Viking Therapeutics (VKTX) and Zealand Pharma report a successful phase 2 for weight loss drugs. Maurits Pot discusses the emergence of strong weight loss drug players.
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN DIEGO , March 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...
Three-Stock Lunch: Super Micro Computer, Deckers Outdoor, and Viking Thera
Jerry Castellini, CastleArk Management co-founder, joins 'Power Lunch' to discuss plays for three stocks, including Super Micro Computer, Deckers Outdoor, and Viking Thera.
Viking Therapeutics emerges as a strong weight loss drug player — or takeover target
Some Wall Street analysts said Viking's experimental obesity treatment may be "best-in-class" following the release of midstage trial data.
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...
Viking Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and...
More transparency in pharmaceuticals will be a tailwind for the space, says BMO's Evan Seigerman
Evan Seigerman, BMO biotech analyst, joins 'Power Lunch' to discuss the health care ecosystems in pharmaceuticals.
Viking Therapeutics' stock more than doubles as investors cheer cheap entry to weight-loss-drug craze
Viking Therapeutics Inc.'s stock soared 120% Tuesday to a record high, after the company announced positive results from a Phase 2 trial of its weight-loss drug VK2735, a GLP-1 receptor agonist that i...
Viking Therapeutics (VKTX) Gains as Patients Lose Weight
Viking Therapeutics (VKTX) soars on weight loss drug trials. Renita Young discusses this as 88% of patients tested achieved at least 10% weight loss.
Cramer's Stop Trading: Viking Therapeutics
CNBC's Jim Cramer explains why he is keeping an eye on shares of Viking Therapeutics.
Viking Therapeutics stock doubles on weight-loss drug trial results
Viking Therapeutics Inc (NASDAQ: VKTX) more than doubled on Tuesday after reporting positive results of a trial involving its weight-loss drug. Viking's GLP-1 significantly reduces weight VK2735 helpe...